TY  -  
T1  - Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial 
SN  -  /  
UR  - http://hdl.handle.net/10138/329571 
T3  -  
A1  - Kellokumpu-Lehtinen, Pirkko-Liisa; Marttila, Timo; Jekunen, Antti; Hervonen, Petteri; Klintrup, Katariina; Kataja, Vesa; Utriainen, Tapio; Luukkaa, Marjaana; Leskinen, Markku; Pulkkanen, Kalevi; Kautio, Anna-Liisa; Huttunen, Teppo 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Background/Aim: Our phase III trial showed that biweekly docetaxel (D) is better tolerated than triweekly D in metastatic castration-resistant prostate cancer (mCRPC). The safety of biweekly cabazitaxel (CBZ) post-docetaxel was studied in mCRPC. Patients and Methods: Altogether, 60 patients received CBZ 16 mg/m2 i.v. on day 1 and day 14 of a 4-week cycle. The mean serum PSA levels were 305 ng/ml, and the mean age 67 years. The primary endpoint was safety according to CTCAEv4.0. Results: A total ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - mCRPC; cabazitaxel; postdocetaxel; biweekly dosing; MITOXANTRONE PLUS PREDNISONE; INCREASED SURVIVAL; PHASE-III; THERAPY; RECOMMENDATIONS; ENZALUTAMIDE; ABIRATERONE; MANAGEMENT; 3122 Cancers 
N1  -   
PP  -  
ER  -